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ABSTRACT 
Aggregated and protease-resistant mammalian prion protein (PrPSc) is the primary protein 
component of infectious prions.  Enriched PrPSc preparations are often used to study the 
mechanisms underlying prion disease.  However, most enrichment procedures are relatively non-
specific and tend to yield significant amounts of non-PrPSc components, including various 
proteins that could confound functional and structural studies. It is thus important to identify 
these proteins and assess their potential relevance to prion pathogenesis.  Following proteinase K 
treatment and phosphotungstic acid precipitation of brain homogenate, we have used mass 
spectrometry to analyze the protein content of PrPSc isolated from prion-infected mice, multiple 
cases of sporadic Creutzfeldt-Jakob disease (sCJD), and human growth hormone associated cases 
of iatrogenic CJD (iCJD).  Creatine kinase was the primary protein contaminant in all PrPSc 
samples while many of the other proteins identified were also found in non-CJD controls, 
suggesting that they are not CJD specific.  Interestingly, the Alzheimer’s disease associated 
peptide amyloid β 1-42 (Aβ1-42) was identified in the majority of the sCJD cases as well as non-
CJD age-matched controls while apoliprotein E was found in greater abundance in the sCJD 
cases.  By contrast, while some of the iCJD cases showed evidence of higher molecular weight 
Aβ oligomers, monomeric Aβ1-42 peptide was not detected by immunoblot and only one case 
had significant levels of apolipoprotein E.  Our data are consistent with the age-associated 
deposition of Aβ1-42 in older sporadic CJD and non-CJD patients and suggest that both 
apolipoprotein E and Aβ1-42 abundance can differ depending upon the type of CJD.  
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INTRODUCTION 
Prion diseases are a group of neurodegenerative disorders that affect various mammals 
including humans1. A critical event in prion pathogenesis is the misfolding of normal host-
encoded prion protein (PrPC) into a pathological isoform, termed PrPSc, that is more protease 
resistant and higher in β-sheet structure than its precursor, PrPC 2. Prion disease is usually 
confirmed postmortem by the deposition of protease-resistant PrPSc, brain tissue vacuolation, and 
gliosis3. The most common form of human prion disease is sporadic Creutzfeld-Jakob disease 
(sCJD)4, 5, which occurs at a yearly rate of approximately 1-2 cases per million people6, 7 and is 
believed to result from the spontaneous misfolding of PrPC into PrPSc. Acquired forms  of CJD 
such as kuru, variant CJD, and iatrogenic CJD (iCJD) represent a relatively small percentage of 
all CJD cases5, 8.  In multiple countries around the world including the United Kingdom, France 
and the United States, iCJD has been associated with exposure to CJD contaminated, cadaver-
derived human growth hormone preparations as well as other contaminated medical products or 
procedures9.  
Prions display a wide range of observable phenotypes indicative of distinct strains10.  
Strains in CJD are defined genetically by a methionine or valine polymorphism at residue 129 in 
PrPC, biochemically by the molecular mass of PrPSc, and neuropathologically by characteristic 
patterns of PrPSc deposition, neuronal vacuolation, and gliosis4.  Using these criteria, 5 strains of 
CJD have been defined:  MM1/MV1, MV2/VV2, MM2c, MM2t and VV14. The precise 
molecular basis of prion strains remains poorly defined but differences in PrPSc  conformation are 
thought to be a primary source of strain variability2.  
Given the central importance of PrPSc in prion pathogenesis, highly enriched PrPSc 
preparations are often used to study the mechanisms underlying prion disease.  Several methods 
for the enrichment of PrPSc from infected brain tissue, most often from laboratory animal models, 
have emerged over the last three decades11-18. However, the procedures used are relatively non-
specific and often yield variable concentrations of diverse molecular species including proteins 
other than PrPSc.  Polysaccharides19, fatty acids20, metal ions21, nucleic acids11, 22 and ferritin11, 23, 
24 are known to co-purify with PrPSc.  Whether or not all of these compounds represent artifacts 
of the enrichment procedure or are functionally associated with PrPSc is unclear.  Indeed, a 
comparison of multiple studies profiling the proteins in PrPSc preparations shows that they can be 
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widely variable23-27.  Thus, it is likely that most of these proteins are present due to the particular 
enrichment protocol used rather than any mechanistically significant affinity with PrPSc.  
Identification of the non-PrPSc proteins in these preparations is of critical importance, especially 
since it has been shown that such contaminants can interfere with structural studies of PrPSc 24. 
A more recent, yet widely used, method for PrPSc isolation from prion-infected tissue is 
sodium phosphotungstic acid (PTA) precipitation28-30. Isolation of PrPSc with PTA is much faster 
and generally requires less sample than many of the more conventional methods that have been 
developed and its utility and convenience has been well documented28-30.  It has been proposed 
that the affinity between the sodium salt of PTA and PrPSc is based upon multivalent electrostatic 
interactions between the polyoxometalate anions and PrPSc aggregates30, 31. Such interactions 
might lead to other multivalent or aggregated molecules co-purifying with PrPSc that could differ 
significantly from those contaminants derived from more conventional PrPSc enrichment 
techniques which are based upon repeated centrifugation.  However, the identity and prevalence 
of non-PrP impurities in PTA-purified PrPSc is unknown.   
In this study, we used tandem mass spectrometry to identify the major protein 
components that were PTA-precipitated from the brains of mice infected with the 22L prion 
strain or from brain samples of previously characterized32 heterozygous cases of MV1 and MV2 
sporadic and human-growth hormone associated cases of CJD. We found that the major PrPSc-
associated proteins isolated using PTA differed from those isolated using a different method 
developed by Bolton et al. which involves repeated centrifugation of the prion-infected 
material17, 18, 24. A notable exception was apolipoprotein E (apoE), which was present in PrPSc 
isolated using both the PTA and the Bolton procedure, suggesting that apoE might have more 
than a coincidental association with PrPSc. However, apoE was present at significantly higher 
abundance in MV1 sCJD when compared to either MV2 sCJD or iCJD. A similar difference in 
abundance was observed for the Alzheimer’s disease-associated peptide amyloid β 1-42 (Aβ1-
42).  These data suggest that the relative abundance of Aβ1-42 and apoE co-precipitating with 
PrPSc can differ depending upon the CJD type. 
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EXPERIMENTAL PROCEDURES 
Supplies and Reagents. Dithiothreitol (DTT), iodoacetamide, ethylenediaminetetracetic 
acid (EDTA), detergent SB3-14, formic acid (FA) ampules and protein extraction buffer were all 
purchased from Sigma. Trypsin was from Promega. Imperial Coomassie blue stain was 
purchased from Thermo-Fisher Scientific. Protease inhibitors and proteinase K (PK) were 
purchased from Roche Diagnostics. Burdick & Jackson brand acetonitrile (ACN) and water were 
purchased from VWR. SDS-PAGE gels were run using reagents and gels from Life 
Technologies-Invitrogen Corporation with NuPAGE Bis-Tris gels and 4X lithium dodecyl 
sulfate (LDS) sample buffer. The PlusOne Silver Stain kit was from GE Healthcare. 
Phosphotungstic acid (PTA, 2Na2O·P2O5·12WO3·18H2O) and protein extraction reagent (7M 
urea, 2M thiourea, 1% C7BzO) were purchased from Sigma. 
Tissue samples.  Mouse PrPSc was isolated from the brains of clinically positive C57Bl/6 
mice infected with the 22L strain of mouse prions.  The experimental protocol was reviewed and 
approved by the Rocky Mountain Laboratories Animal Care and Use Committee (Animal Study 
Protocol 2003-06).  The Rocky Mountain Laboratories are fully accredited by the American 
Association for Laboratory Animal Care and this study was carried out in strict accordance with 
the recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. 
Brain tissue samples of heterozygous sCJD cases (MV1 and MV2), heterozygous United 
Kingdom human growth hormone-associated iCJD cases (MV2), and non-CJD age matched 
controls were obtained from the National CJD Research & Surveillance Unit Brain and Tissue 
Bank in Edinburgh, UK.  Samples were pseudo-anonymized using a Brain Bank reference 
number and no patient identifiable data was transferred to the NIH. Cerebellar cortex (CbC) and 
cerebral cortex (CC) tissue from two additional sCJD patients were obtained from the University 
of Verona, Italy. These tissues were obtained at autopsy and sent to the Neuropathology Unit at 
the University of Verona for statutory definite diagnosis of CJD. Strain typing and clinical and 
neuropathological features of all but two of the cases examined have been previously reported32. 
All UK cases had consent for research and their supply and use in this study was covered by 
LREC 2000/4/157 (National Creutzfeldt-Jakob disease tissue bank: acquisition and use of 
autopsy material for research on human transmissible spongiform encephalopathies, Professor 
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James Ironside, amended date: 9th October 2007).  Ethical approval for the acquisition and use of 
human brain material was obtained from the National Institutes of Health (NIH) Office of 
Human Subject Research (Exempt #11763 and #12725). 
Enrichment of PrPSc from brain homogenate by PTA precipitation. PrPSc enrichments 
using PTA precipitation were done using 10% brain homogenates (50mg brain equivalents) 
prepared in PBS and mixed with an equal volume of 4% sarkosyl/phosphate buffered saline 
(PBS) and treated with 50 units of benzonase. Brain lysate was cleared by a 5 min centrifugation 
at 5,000 g and then digested with 50 µg/mL PK for 1 hr at 37 °C. Following the addition of PTA 
at a final concentration of 0.3%, the samples were incubated at 37 °C for 2 hr and subjected to 
centrifugation at 16,000 g for 30 min. The resultant pellets were twice washed: first with 200mL 
PBS containing 200mM EDTA and then PBS alone at pH 8 for 30 min and subjected to 
centrifugation as before. Each sCJD, iCJD or non-CJD control sample was subjected to 3 or 
more individual PTA precipitations, each of which represented a single technical replicate.  
SDS-PAGE and in-gel tryptic digestion. Pellets containing enriched PrPSc were 
suspended in 25 µL of protein extraction buffer (Sigma) and incubated at 37 ºC for 30 min. The 
sample was reduced with 14mM DTT prior to alkylation with 75mM iodoacetamide for 30 min 
at room temperature in the dark with orbital rotation. The reaction was quenched by dilution of 
1M DTT to a final concentration of ~200mM. Life Technologies 4X LDS sample buffer was 
added, resulting in a final sample volume of approximately 50µL. Each sample was heated to 
100 °C using a heating block and subjected to centrifugation (22,000 g) for 5 min prior to 
loading onto an SDS-PAGE NuPAGE 10% Bis-Tris 1.5mm gel. Gels were run in 2N-
morpholinoethanesulfonic acid (MES) running buffer at 175V for 20 min, stained with 
Coomassie blue Imperial stain (Thermo-Fisher Scientific), and then destained with water prior to 
band selection for in-gel trypsin digestion. For every PTA preparation, one lane of a gel was cut 
into 8 slices each containing Coomassie blue stained material. Trypsin digestion of each band 
was conducted overnight in a mixture of 5% trifluoroethanol in 50mM ammonium bicarbonate, 
pH 8.0 at 37 ºC. The digests were quenched 16 hrs later with 10µL of 8% aqueous FA, then 
transferred to a fresh vial. The original gel slices were further extracted with 60% acetonitrile in 
water, then added to the fresh vials. The resulting peptide solutions were dried by centrifugal 
vacuum. Each digest was dissolved in 20µL of HPLC buffer A (water/3% ACN/0.1% FA), 
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subjected to centrifugation at 22,000 g and the upper 16µL transferred to an autosampler vial for 
LC-MS/MS analysis.  
Western blotting. Proteins were separated by SDS-PAGE as described above and 
transferred to polyvinylidene fluoride (PVDF) membrane by wet transfer using Towbin’s buffer. 
For mouse tissues, the samples were probed with the mouse monoclonal anti-PrP antibody 6D11 
(Covance, Inc.) at a dilution of 1:5,000. 6D11 recognizes residues 93-109 of mouse PrP. Human-
derived samples were probed with the mouse monoclonal anti-PrP antibody 3F4, which 
recognizes residues 109-112 of human PrP, at a dilution of 1:2,000.  The secondary antibody was 
horseradish peroxidase (HRP) labeled anti-mouse IgG secondary antibody (GE Healthcare) at a 
dilution of 1:100,000 and the blot was developed on film with ECL Plus Femto according to the 
instructions from the manufacturer. For the detection of the amyloid β 1-42 (Aβ1-42) peptide, 
samples were first suspended in denaturing buffer (7M urea, 2M thiourea, 1% C7BzO) and then 
diluted 1:1 with 2X sample buffer (Life Technologies) for SDS-PAGE as detailed above.  
Membranes were developed with the anti-amyloid precursor protein mouse monoclonal antibody 
6E10, which recognizes residues 1-16 of Aβ1-42, at a dilution of 1:5,000. 
HPLC chip-based nanospray LC-MS/MS. Proteins were identified by LC-MS/MS using 
an Agilent 1200 connected to an XCT Ultra 6300 Ion Trap via a nanospray source and a 
microfluidic HPLC chip interface. Tryptic digests were loaded onto the chip (Agilent, Zorbax 
300SB-C18, 5µm, 75µm x 43mm) with an autosampler and washed with Buffer A prior to 
elution at 300nL/min. The step gradient was 3 - 30% Buffer B (90% ACN/0.1% FA) over 30 
min, to 50% B by 40 min, 90% B by 60 min, 97% B by 70 min, and back to 3% B by 78 min. 
Runs were followed by 4 min of  post-run equilibration with Buffer A. External calibration was 
done using a tuning mix (Agilent) specific for the ion trap. Data-dependent MS acquisition was 
performed with air flow set to 4L/min at 350 ºC, MS capillary voltage 1800-1850V, maximum 
accumulation time 150ms, with a target maximum of 100,000. The MS scan range was set to 300 
– 1400 m/z in the Ultrascan mode. Four parent ions were selected for each MS/MS cycle with a 
fragmentation amplitude of 1.0V and the SmartFrag setting on.  
Data analysis and protein identification. Raw data were processed into peak lists using 
MASCOT Distiller v2.4.3.0. The MGF files were searched against a target database filtered for 
human or mouse taxonomy (www.uniprot.org) using MASCOT Daemon. The search parameters 
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for MASCOT protein identification33 utilizing trypsin/P search parameters consisted of one 
missed tryptic cleavage allowed with a fixed carbamidomethylation (+57, Cys) and a variable 
oxidation (+16, Met). Mass tolerances of 2.0 and 1.0 Daltons were used for parent and 
monoisotopic fragment ions, respectively. The DAT result files from MASCOT were used as 
input files for further analysis using the ProteoIQ v2.6.02 bioinformatics platform (Premier 
Biosoft Inc)34. A comprehensive list of protein identifications was derived using >2 peptides 
with unique m/z values, MASCOT ion scores of ≥ 30 and protein group probabilities of ≥ 0.935.  
A more stringently filtered set of identifications for the purpose of listing only the most abundant 
proteins was derived from a MASCOT ion score threshold of >40, at least 2 peptides with unique 
m/z values, and protein and peptide probabilities of at least 0.99 or 0.9, respectively according 
the Protein and Peptide Prophet algorithms35, 36. In the case of amyloid beta A4 protein, hereafter 
referred to as Aβ, only one tryptic peptide (KLVFFAEDVGSNK) corresponding to residues 17-
28 in the Aβ1-42 portion of the protein was consistently identified. When the trypsin-only 
constraints were removed from the search parameters another peptide (GAIIGLMVGGVVIA) 
corresponding to Aβ1-42 residues 29-42 was confirmed.  Each peptide was allowed only a single 
protein identification according to criteria used in the ProteoIQ bioinformatics platform34. Thus, 
the strongest identifications were based upon the highest number of spectral counts, the highest 
cumulative MASCOT ion scores, the highest protein/peptide prophet probabilities, and the 
greatest number of unique peptides. Keratin was considered an environmental contaminant and 
was removed from the final protein lists. Spectral counts were used to semi-quantify the amount 
of each protein identified in the final PrPSc preparation.  Percentages were calculated by dividing 
the number of mass spectra observed for a given protein by the total number of mass spectra 
multiplied by 100. 
Statistics.  Mean and standard deviation (SD) or standard error of the mean (SEM) were 
derived using the individual technical replicates described above.  A 1-Way ANOVA with 
Dunnett’s post-test or a Tukey’s multiple comparisons test was used to compare multiple data 
sets. All calculations were done using the GraphPad Prism software package, version 6.04. 
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RESULTS 
LC-MS/MS analysis of PrPSc PTA-precipitated from 22L-infected mouse brains. 
Western blot analysis of total PrP in 22L versus normal brain homogenate (NBH) inoculated 
mice showed a significantly higher concentration of PrP in the 22L infected brain homogenate 
(Fig. 1A, lanes 1-2).  Treatment of the brain homogenates with PK followed by PTA 
precipitation led to an almost complete loss of PrP signal in the NBH-inoculated sample but not 
the 22L-infected sample, indicating that the vast majority of PrP present in the PTA precipitate 
from 22L-infected brain was PrPSc (Fig 1A).  In the absence of PK treatment, a very small 
amount of aggregated PrPC from mice inoculated with NBH was detected in the PTA precipitate 
(Fig. 1A, lane 7). This is consistent with previous reports that uninfected mammalian brain may 
contain small amounts of detergent-insoluble PrP aggregates susceptible to precipitation with 
PTA37, 38 which may comprise up to 5% of the PrP recovered39. 
Staining of the samples with either silver nitrate (Fig. 1B, lanes 1-4) or Coomassie blue 
(Fig. 1B, lanes 5-8) revealed that numerous non-PrP proteins were also precipitated by PTA. 
However, because PK treated PTA precipitates from prion infected brain are known to be highly 
infectious29 and therefore must contain all of the critical components that constitute an infectious 
prion, we analyzed the proteins present in the less heterogeneous PK-treated PTA precipitates 
using LC-MS/MS.  Since it is known that the protein concentration in a sample correlates 
reasonably well with the number of mass spectra assigned to that particular protein40, spectral 
counting was used as a semi-quantitative method to estimate the relative abundance of each 
protein. We detected a limited number of PrP peptides in the uninfected NBH inoculated sample 
(Table 1). However, in samples derived from 22L-infected mouse brain, PrP peptides were 
present at much higher levels than in the uninfected samples and PrP was the most abundant 
PTA-precipitated protein, represented by an average over two independent experiments of 54% 
of the peptides found (Table 1).  
We next compared the purity of PrPSc isolated by PTA precipitation to PrPSc isolated 
from the same starting brain homogenate using an enrichment protocol derived from the 
centrifugation-based method of Bolton et al.18.  The relative PrPSc enrichment levels were similar 
for both the PTA and Bolton preparations (Figure 1C).  The protein composition of the material 
isolated using the method of Bolton et al. (Supplemental Table 1) was comparable to what we 
have previously reported24, 25 with ferritin heavy and light chains comprising the major impurities 
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(Figure 1C). By contrast, dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex (Dlat) and creatine kinase (CK) were the major non-PrPSc proteins 
associated with the PTA precipitate.  Creatine kinase was also the most abundant protein in 
uninfected, PK-treated and PTA precipitated mouse brain homogenate (Table 1) indicating that 
its presence in PTA-precipitated PrPSc was not related to prion infection.  Neither Dlat nor CK 
were detected in the Bolton-derived preparations (Figure 1C). Overall, the data show that a 
single round of PTA precipitation and PK treatment leads to an enrichment of 22L mouse PrPSc 
similar to that from centrifugation-based techniques but with different protein contaminants. 
LC-MS/MS analysis of PrPSc PTA-precipitated from sCJD brain tissue. We next 
examined the protein content of PrPSc isolated following PK treatment and PTA precipitation 
from 19 samples of heterozygous MV1 or MV2 sCJD (Fig. 2A). The clinical and molecular 
characteristics of these cases, the majority of which have been described in a previous study32, 
are briefly summarized in Table 2.  A comprehensive list of protein identifications is shown in 
Supplemental Table 2 and a stringently filtered list showing only the most abundant proteins is 
given in Table 3.  As with mouse prion derived PTA-precipitated PrPSc, CK was a major 
impurity in all of the PTA precipitated human samples including three non-CJD age matched 
controls (Table 3). A total of 5 PrP peptides were detected in one of the three non-CJD cases and 
this was set as the background threshold for PrPC.  Consistent with the presence of PrPSc, PrP 
peptides were detected at well above the threshold level of >5 spectral counts in all of the sCJD 
samples (Fig. 2C).  Some sCJD samples, however, had much lower levels of PrPSc relative to 
other sCJD samples (Figure 2A).  In these latter samples, the contribution of CK and other co-
precipitating proteins as a percentage of the mixture was much higher. 
 The majority of precipitated proteins from both MV1 and MV2 sCJD were identical, with 
11 of the 16 most abundant proteins (69%) present in both sCJD types (Table 3).  Many of them 
were found not only in the majority of the sCJD cases examined but also in the age-matched 
non-CJD neurological controls (Table 3 and Fig. 3), indicating that they were not prion disease 
specific.  Proteins common to all four groups included CK, Dlat, mammalian ependymin-related 
protein 1 (MERP-1), and collagen α chain (Table 3).  The handful of top proteins that were 
present in a single group, such as complement C1q in MV1 CJD or versican and glial fibrillary 
acid protein (GFAP) in MV2 CJD, have also been found in PrPSc preparations from prion 
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infected mice and are likely related to the response of the brain to damage during the late stages 
of prion disease25, 41,42 
LC-MS/MS analysis of PrPSc PTA-precipitated from iCJD brain tissue. In order to 
determine if there were relevant differences in the proteins co-precipitating with PrPSc between 
sporadic and iatrogenic CJD cases, 7 cases of heterozygous MV2 iCJD (Table 2) associated with 
exposure to contaminated human growth hormone in the UK were also analyzed.  PrPSc was 
detectable in all of the iCJD cases by both western blot (Figure 2B) and MS (Table 3), although 
the relative abundance varied from case to case (Fig. 2C).  The diversity of proteins identified in 
PrPSc isolated from iCJD brain tissue was low (Supplemental Table 2). Only seven high 
abundance proteins were identified in these samples, including CK and Dlat (Table 3).  None 
were unique to the iCJD cases and most were found in the non-CJD controls (Table 3 and Fig. 
3).  Thus, many of the proteins found in PrPSc preparations from the sCJD and non-CJD controls 
were not found in the iCJD samples (Table 3 and Fig. 3). 
Comparison of PrPSc PTA-precipitated from different brain regions. Our initial analysis 
of PTA precipitated PrPSc from sCJD brain tissue suggested that most of the proteins identified 
were not prion disease specific.  To determine whether the same was true of PrPSc isolated from 
different regions of the same sCJD brain, PrPSc was PTA-precipitated from both the cerebellar 
(CbC) or cerebral (CC) cortex from 4 sCJD cases (Fig. 4).  PrPSc was found in similar abundance 
in the CbC and CC for all of the cases examined except case 7, where the CbC had twice as 
much PrPSc when compared to the CC.  For each case examined, there were some proteins that 
were found in one region of the brain and not the other.  For example, in case 7 apoE was 
detected in the CbC and not the CC and contributed 5% of the total peptides identified.  Other 
proteins that varied from case to case were also of relatively low abundance, for example myelin 
proteolipid protein (PLP) in case 9.   The low abundance of these proteins suggests that their 
regional variability may be related to the level of sensitivity of the MS/MS assay rather than to 
region-specific differences in the proteins that consistently co-precipitate with PrPSc. 
Identification of proteins associated with Alzheimer’s disease in CJD brain tissue.  We 
and others have shown that apolipoprotein E (apoE), a protein associated with Alzheimer’s 
disease pathogenesis, consistently co-purifies with PrPSc isolated from prion-infected brain23-26 
suggesting that the two proteins may interact.  In PrPSc precipitated from CJD brain tissue, apoE 
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was present in 15 out of the 26 total CJD brains analyzed and was detected at very low levels in 
2 of the 3 non-CJD controls (Figure 5A).  Interestingly, the prevalence of apoE differed 
depending upon the type of CJD.  In PrPSc isolated from MV1 cases of sCJD, 6 of the 7 samples 
had relatively high amounts of apoE while only 6 of the 12 samples of PrPSc from MV2 cases of 
sCJD were apoE positive (Fig. 5A).  The difference in apoE abundance between sCJD MV1 and 
the non-CJD control samples was statistically significant (p=0.01, Fig. 5C).  Only one of the 7 
iCJD MV2 PrPSc samples had significant numbers of apoE peptides (Fig. 5A, case 19) and the 
average abundance of apoE peptides in the iCJD samples more closely resembled that of the 
sCJD MV2 samples (Fig. 5C).  The differences in apoE abundance between MV1 and MV2 CJD 
was likely not due to PrPSc sample variability since the relative average abundance of PrPSc was 
similar between sample groups (Fig. 2C). Thus, our data suggest that the association of apoE 
with human PrPSc may vary by CJD subtype. 
In 15 out of 19 (79%) of the sCJD brain samples and in all 3 of the non-CJD controls, 
peptides derived from the Aβ were detected (Fig. 5B). Aβ peptides were present at a similar 
abundance in both sCJD MV and the non-CJD age-matched control samples (Fig. 5C).  By 
contrast, the abundance of these peptides was low in PTA-precipitates from sCJD-MV2 and they 
were not detected in the 7 iCJD cases examined (Fig. 5B).  The relative average abundance of 
Aβ was thus significantly lower in these cases when compared to the non-CJD controls.  
Interestingly, Aβ and apoE were not always detected in the same sample (compare Fig. 5A and 
B) suggesting that the presence of one is not indicative of the presence of the other.  Overall, our 
data suggest that, like apoE, the presence of Aβ in human PrPSc preparations may vary by CJD 
type. 
Alzheimer’s disease-associated Aβ1-42 peptide in PTA-precipitates from CJD brain.  A 
recent study has found Alzheimer’s disease-associated Aβ peptide 1-42 (Aβ1-42) positive 
plaques in some human growth hormone-associated cases of iCJD in the UK43. Aβ1-42 positive 
plaques were not found in age-matched sCJD controls, raising the possibility of iatrogenic 
transmission of Aβ1-42 pathology43.  Our MS analysis of PTA-precipitated PrPSc used samples 
from the same cohort of iCJD cases32 but we only detected peptides from the Aβ protein in the 
sCJD samples.  If these peptides were from regions of the Aβ protein outside of Aβ1-42, it could 
help to explain the discrepancy between our results and those of Jaunmuktane et al.43. However, 
the mass spectrum of the most common tryptic Aβ peptide identified corresponded specifically 
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to residues 17-28 of the Aβ1-42 peptide (Fig. 6A).  Furthermore, a second non-tryptic peptide 
corresponding to residues 29-42 of Aβ1-42 was also identified (Figure 6B). Thus, residues 17-42 
of Aβ1-42 were found in sCJD MV1 and MV2 as well as in the non-CJD neurological controls 
but not in any of the iCJD samples.   
The consistent identification of Aβ1-42 peptides and the corresponding lack of peptides 
corresponding to full length Aβ protein strongly suggested that Aβ1-42 was present in the sCJD 
samples. In order to determine if the MS results correlated with the presence or absence of Aβ1-
42 in PTA precipitates from CJD brain, we analyzed non-PK treated, PTA precipitates for the 
presence of the Aβ1-42 peptide by western blot.  In the 3 representative sCJD samples tested, a 
peptide corresponding to Aβ1-42 as well as a high molecular weight smear consistent with the 
presence of Aβ oligomers44, were detected (Fig. 7). A high molecular weight smear was also 
detected in 4 of the 7 iCJD samples, although a band consistent with monomeric Aβ1-42 was not 
found (Fig. 7).  The immunoblot results are consistent with the MS data and confirmed the 
presence of Aβ1-42 in PrPSc preparations isolated from the sporadic, but not iatrogenic, cases of 
CJD analyzed.  However, the presence of Aβ1-42 positive high molecular weight species in the 
iCJD samples suggests that SDS insoluble aggregates of Aβ1-42 are likely present in at least 
some cases of human-growth hormone associated iCJD. 
 
DISCUSSION 
 The presence of Aβ1-42 in the majority of PTA precipitates from the sCJD samples 
tested is consistent with studies showing that Aβ1-42 can co-localize with PrPSc in amyloid 
plaques in the brains of sCJD patients45, 46.  Thus, the co-precipitation of Aβ1-42 with PrPSc may 
indicate that the two proteins can interact in vivo.  However, we also detected residues 17-42 of 
Aβ1-42 in PTA precipitates from all 3 of the age-matched, non-CJD brain samples examined, 
indicating that Aβ1-42 was also present in these samples.  While one of these cases was 
diagnosed pathologically as Lewy body dementia, the other two died of non-neurological 
causes32. It is not surprising that that there was positivity to Aβ in the Lewy body dementia case 
as co-occurrence of aggregated proteins is not unusual in neurodegeneration as well as aging.  
This suggests that the co-occurrence of Aβ1-42 and PrPSc in prion infected brain may be more an 
age related phenomenon than a direct consequence of either prion infection or interaction with 
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PrPSc.  A large scale study comparing the frequency of the co-occurrence of Alzheimer’s 
pathology in over 100 cases of sCJD with age-matched, non-CJD control brain samples reached 
a similar conclusion45.  If age is a driving factor for the deposition of Aβ1-42 in sCJD, then its 
presence in PTA precipitates from sCJD brain may be primarily due to its physical properties. 
  A recent study of several cases from the same cohort of human growth hormone-
associated cases of iCJD as the current study found Aβ1-42 positive plaques and Aβ1-42 peptide 
in 4 out of 8 of the brain samples examined43, and there have been several cases of iCJD with 
coincident Alzheimer’s pathology associated with dura mater transplant47-49. The co-occurrence 
of Aβ1-42 and PrPSc has been suggested in these cases to be an incidental finding47, a result of 
iatrogenic transmission of Alzheimer’s disease43, or the consequence of seeding of underlying 
brain tissue by Aβ present in the dura mater graft49. We were unable to detect the Aβ1-42 
peptide, by either MS or immunoblot, in 7 samples of iCJD brain.  However, we cannot rule out 
the possibility that we failed to detect monomeric Aβ1-42 due to an inability of PTA to 
quantitatively precipitate Aβ1-42 aggregates from brain tissue.  In 4 of the 7 iCJD cases 
examined by western blot, we did detect a high molecular weight smear consistent with the 
presence of SDS insoluble Aβ oligomers44. The presence of higher molecular weight Aβ species 
in some of the iCJD brain samples assayed is consistent with the conclusion of Jaunmuktane et 
al.43 that Aβ amyloid can be present in human growth hormone associated cases of iCJD from 
the UK. 
Previous work based on either genotyping50, 51 or the allotype ratio of M129 to V129 in 
PrPSc 32 has suggested that human growth hormone related cases of iCJD in the UK are the result 
of exposure to the MV2/VV2 strain of sCJD.  In the current work, the relative average 
abundance of apoE and Aβ1-42 peptides was statistically indistinguishable in PrPSc preparations 
from the sporadic and iatrogenic MV2 samples and clearly differentiated these cases from the 
MV1 cases examined (Fig. 5C).  These data are consistent with the hypothesis that human 
growth hormone-associated cases of iCJD in the UK are related to exposure to the MV2 strain of 
sCJD. Moreover, the fact that the number of Aβ1-42 and apoE peptides associated with PrPSc is 
higher in MV1 versus MV2 cases of sCJD suggests that their abundance may differ depending 
upon CJD subtype which may be related to variables such as age at infection, PrPSc 
conformation, degree of prion spread, or rate of prion accumulation. 
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With the exception of PrPSc itself, apoE was the only other protein specific to both PrPSc 
enrichment procedures.  This is the case not only in the current studies but also in other PrPSc 
samples that have been profiled23-26. ApoE has been implicated as a biomarker for prion 
disease27, 52, co-localizes with PrPSc deposits in vivo53, and is present at significantly elevated 
levels in mice infected with different prion strains41.  The consistent presence of apoE in 
enriched PrPSc samples coupled with the fact that it is overrepresented in MV1 cases of sCJD 
when compared to non-CJD controls (Fig. 5C), could suggest a potential interaction with PrPSc. 
However, if PrPSc and apoE are directly interacting, the stoichiometry of that interaction is 
unclear.  In each CJD case we examined, the relative apparent abundance of PrPSc was much 
higher than that of apoE.  It is plausible that the PK treatment step utilized during purification is 
digesting a higher proportion of apoE than PrPSc itself.  Alternatively, the presence of apoE in 
PrPSc samples may be related to its involvement in cholesterol and lipid transport which appear 
to be altered during clinical prion disease41. 
The utility and convenience of PTA-based precipitation has been well documented28-30, 39, 
54 and PTA precipitated PrPSc has been used to study various aspects of prion pathogenesis 
including PrPSc uptake55.  Our MS analysis shows that PK treatment followed by PTA 
precipitation of 22L-infected mouse brain homogenate yields an approximate 50% abundance of 
PrPSc relative to other proteins, similar to that seen when using the centrifugation-based 
enrichment protocol first developed by Bolton et al. (Fig. 1)18. Thus, there are significant levels 
of non-PrP proteins in both preparations that could potentially confound molecular, biochemical, 
or structural studies. We have identified the primary protein contaminant in PTA-purified PrPSc 
as creatine kinase, an enzyme active in the brain and other tissues that effects the conversion of 
creatine to phosphocreatine.  The primary contaminant previously identified by us and others in 
PrPSc preparations has been ferritin rather than creatine kinase23-26. The fact that different 
contaminants are consistently associated with PrPSc enriched using different methods suggests 
that their presence in these samples is a function of their physical properties rather than any 
functional association with PrPSc. 
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SUPPORTING INFORMATION: 
The following files are available free of charge at ACS website http://pubs.acs.org: 
Moore et al Supplemental Table 1.docx.  Proteins identified in PrPSc purified from 22L-infected 
and uninfected brain homogenate using the method of Bolton et al. 
Moore et al Supplemental Table 2.xlsx.  Proteins identified in PrPSc PTA-precipitated from CJD 
and non-CJD brain samples. 
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Table 1. Proteins identified after PTA precipitation of 22L-infected and uninfected mouse 
brain homogenate. 
 
aProtein identifiers are from www.uniprot.org. 
bDihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex 
cThe total number of assigned spectra (spectral counts or SpC) from two independent PTA 
purifications. 
dThe number of unique peptides from two independent PTA purifications. 
dThe sum of the highest MASCOT peptide scores for each unique peptide.  
fThe average percent relative abundance of each protein based upon the sum of spectral counts 
from two independent replicates.  Positive protein identifications required at least 2 peptides with 
unique m/z values and MASCOT ion scores of ≥ 40.  
IDa PTA associated proteins (22L) Prep1 Prep2 SpCc Unique peptidesd 
Total 
scoree % total
f 
P04925 Major Prion protein    545 15 1015.5 53.6 
Q8BMF4 Dlatb   195 10 747.8 19.2 
P30275 Creatine kinase U-type, mitochondrial    97 10 540.3 9.5 
P55066 Neurocan core protein    47 6 352.7 4.6 
P60202 Myelin proteolipid protein    24 5 285.1 2.4 
P08226 Apolipoprotein E    22 6 363.5 2.2 
Q9ES97 Reticulon-3    15 2 156.5 1.5 
P11087 Collagen alpha-1(I) chain    14 3 172.9 1.4 
Q99104 Myosin-Va   12 3 159.7 1.2 
P10493 Nidogen-1   8 3 155.2 0.8 
Q9R171 Cerebellin-1   8 2 134.3 0.8 
Q60994 Adiponectin    7 3 168.5 0.7 
P62702 40S ribosomal protein S4, X isoform   5 2 89.1 0.5 
Q80SY4 E3 ubiquitin-protein ligase MIB1    4 3 153.8 0.4 
P63082 V-type proton ATPase 16 kDa proteolipid subunit    4 2 134.4 0.4 
Q5SV85 Synergin gamma   3 2 91.7 0.3 
Q9D2P8 Myelin-associated oligodendrocyte basic protein   3 2 89.1 0.3 
P03893 NADH-ubiquinone oxidoreductase chain 2   2 2 94.4 0.2 
Q64521 Glycerol-3-phosphate dehydrogenase, mitochondrial   2 2 87.3 0.2 
 
PTA associated proteins (uninfected) 
      
P30275 Creatine kinase U-type, mitochondrial   --- 32 8 461.1 76.2 
P04925 Major Prion protein   --- 8 3 151.4 19.0 
P60202 Myelin proteolipid protein   --- 2 2 89.3 4.8 
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Table 2.  Clinical and molecular features of heterozygous (MV) CJD cases analyzed. 
 
sCJD 
Case ID 
Numbers 
Gendera 
Age of 
Onset (yrs)b 
Duration 
(mo)c 
Brain 
Regiond 
Molecular Subtype Reference 
1-5 4M and 1F 53-77 4-14 CC, CbC MV1 32 
21 M 86 6 CC MV1 This paper 
6-14 4M and 5F 57-75 7-21 CC, CbC MV2 32 
iCJD 
15-20 3M and 3F 27-33 8-32 CC MV2 32 
22  M 28 15 CC MV2 This paper 
 
aNumber of male (M) and female (F) cases. 
bAge of onset in years (yrs). 
cDisease duration in months (mo). 
dCC = cerebral cortex; CbC =  cerebellar cortex.
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Table 3.  The most commonly observed proteins PTA-precipitated with PrPSc from PK-treated sporadic, 
iatrogenic and non-CJD brain tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Genea Major proteinsb, c Commonly observed peptide Total ion scored 
Unique 
peptidese 
CJD 
MV1 
(n=7) 
CKMT1A Creatine kinase U-type (P12532) TVGMVAGDEETYEVFADLFDPVIQER 1306 17 
PRNP Prion protein (P04156) HMAGAAAAGAVVGGLGGYMLGSAMSR 1545 19 
DLAT Dlat (P10515) GVETIANDVVSLATK 607 8 
APP Amyloid β A4 protein or Aβf(P05067) LVFFAEDVGSNK 100 2 
LTF Lactotransferrin (P02788) LADFALLCLDGK 1408 21 
APOE Apolipoprotein E (P02649) GEVQAMLGQSTEELR 587 8 
COL1A2 Collagen α-2 (CP08123) GETGPSGPVGPAGAVGPR 238 3 
MERP-1 MERP-1 (Q9UM22) ALLSYDGLNQR 265 3 
PLP1 Myelin proteolipid protein (P60201) MYGVLPWNAFPGK 371 6 
TNXB Tenascin-X (P22105) CVCDPGYTGDDCGMR 537 8 
APCS Serium amyloid P-component (P02743) AYSLFSYNTQGR 196 3 
C1QTNF5 Complement C1q TNF (Q9BXJ0) VLVNEQGHYDAVTGK 339 6 
CBLN1 Cerebellin-1 (P23435) TMIIYFDQVLVNIGNNFDSER 303 5 
sCJD 
MV2 
(n=12) 
PRNP Prion protein (P04156) HMAGAAAAGAVVGGLGGYMLGSAMSR 1650 20 
CKMT1A Creatine kinase U-type (P12532) TVGMVAGDEETYEVFADLFDPVIQER 1284 17 
DLAT Dlat (P10515) GVETIANDVVSLATK 745 10 
LTF Lactotransferrin (P02788) LADFALLCLDGK 1954 28 
COL1A2 Collagen α-2 (P08123) GETGPSGPVGPAGAVGPR 306 4 
GFAP Glial fibrillary acidic protein (P14136) LADVYQAELR 968 14 
APP Amyloid β A4 proteinor Aβf (P05067) LVFFAEDVGSNK 100 2 
PLP1 Myelin proteolipid protein (P60201) MYGVLPWNAFPGK 384 6 
MERP-1 MERP-1 (Q9UM22) ALLSYDGLNQR 322 5 
APOE Apolipoprotein E (P02649) GEVQAMLGQSTEELR 659 8 
COL1A1 Collagen α-1 (P02452) DGEAGAQGPPGPAGPAGER 231 3 
CBLN1 Cerebellin-1 (P23435) TMIIYFDQVLVNIGNNFDSER 285 4 
APCS Serium amyloid P-component (P02743) AYSLFSYNTQGR 261 4 
VCAN Versican core protein (P13611) VSVPTHPEAVGDASLTVVK 276 4 
iCJD 
MV2 
(n=7) 
PRNP Prion protein (P04156) HMAGAAAAGAVVGGLGGYMLGSAMSR 1588 23 
CKMT1A Creatine kinase U-type (P12532) TVGMVAGDEETYEVFADLFDPVIQER 1238 17 
DLAT Dlat (P10515) GVETIANDVVSLATK 720 10 
TNXB Tenascin-X (P22105) CVCDPGYTGDDCGMR 758 12 
APOE Apolipoprotein E (P02649) GEVQAMLGQSTEELR 283 4 
MERP-1 MERP-1 (Q9UM22) ALLSYDGLNQR 192 3 
PLP1 Myelin proteolipid protein (P60201) MYGVLPWNAFPGK 176 3 
Non-
CJD 
(n=3) 
CAMK2A CAMK2A (Q9UQM7) ITQYLDAGGIPR 382 6 
CKMT1A Creatine kinase U-type (P12532) TVGMVAGDEETYEVFADLFDPVIQER 735 13 
APP Amyloid β A4 proteinor Aβf (P05067) LVFFAEDVGSNK 100 2 
COL4A2 Collagen α-2-IV (P08572) GEQGFMGNTGPTGAVGDR 479 7 
COL1A2 Collagen α-2 (P08123) GEIGAVGNAGPAGPAGPR 213 3 
MERP-1 MERP-1 (Q9UM22) ALLSYDGLNQR 197 3 
NID1 Nidogen (P14543) QDLGSPEGIAVDHLGR 336 5 
HSPG2 Proteoglycan core protein (P98160) EHLLMALAGIDTLLIR 468 8 
RPL18 60S ribosomal protein (Q07020) ILTFDQLALDSPK 259 4 
LAMC1 Laminin γ-1 (P11047) QDIAVISDSYFPR 375 6 
DLAT Dlat (P10515) GVETIANDVVSLATK 404 7 
FTH1 Ferritin heavy chain (P02794) IQNVVTSFAPQR 228 4 
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a Gene abbreviations and protein names are from www.uniprot.org. 
bKeratin was removed from the protein list and the remaining proteins were filtered based upon a 
MASCOT ions score of ≥40, protein and peptide probabilities of at least 99% and 90% respectively, 
according to the protein prophet and peptide prophet algorithms, and at least 2 peptides with unique m/z 
values required for a protein identification. Each peptide was allowed only a single protein match 
according to the settings of the ProteoIQ bioinformatics platform. The strongest protein identifications, 
based upon the highest number of spectral counts, the highest cumulative MASCOT ion scores, the 
highest protein/peptide prophet probabilities and the greatest number of unique peptides are listed in the 
table above. A more comprehensive list containing additional lower abundance protein identifications is 
provided as Supplemental Table 2. 
cFor simplicity, the proteins Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, Lactotransferrin, Ca/calmodulin-dependent kinase-II-subunit α and 
Mammalian ependymin-related protein 1 are listed in the table by their either their gene names Dlat, 
LTF, CAMK2A, respectively, or abbreviated names (MERP-1). 
dThe sum of the highest MASCOT ion scores derived from each unique peptide. 
eThe number of tryptic peptides with unique m/z values. 
fThe amyloid β A4 protein, abbreviated as Aβ throughout the text, was consistently identified by the 
single tryptic peptide LVFFAEDVGSNK. However, additional MASCOT searches without the 
constraints of trypsin specificity resulted an additional peptide within the amyloid β A4 protein 
sequence. 
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FIGURE LEGENDS 
Figure 1. Proteins which co-purify with PrPSc from the brain homogenate of 22L-infected 
mice differ depending upon the purification protocol used. (A) Immunoblot of 22L-infected 
and NBH-inoculated mouse brain homogenate.  The blot was developed using the anti-PrP 
monoclonal antibody 6D11 which recognizes PrP residues 95-105. PTA precipitation, PK-
treatment, and whether or not the samples were from 22L-infected mice is indicated under each 
lane. Lanes 7-10 represent a longer exposure of lanes 3-6. The major PrPSc bands are indicated 
by the bracket on the right.  (B) Silver stain (lanes 1-4) and Coomassie blue stain (lanes 5-8) of 
PTA-precipitated brain homogenates with and without protease treatment. The major PrPSc bands 
are indicated by the bracket on the right.  (C) Relative percentages of PrPSc and other proteins in 
22L-infected brain homogenates precipitated with PTA (left) or isolated using a centrifugation 
technique based on Bolton et al. (right, modified Bolton)18.  apoE=apolipoprotein E; 
CK=creatine kinase; Dlat=dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex. 
 
Figure 2.  Variable PrPSc content in PK-treated sCJD, iCJD and non-CJD brain 
homogenates.  Samples were analyzed to estimate the relative concentrations of PrPSc in each 
brain homogenate and each lane represents 50µg brain equivalents of brain homogenate that has 
been PK-treated.  (A) PrPSc from 19 sCJD cases.  Three separate gels are shown (lanes 1-7, lanes 
8-14, and lanes 15-23) with excised irrelevant lanes indicated by a thin white line. Exposure 
times were matched based on the intensity of the signal in case 1 (lanes 2 and 22) or case 12 
(lanes 11 and 23).  Standards for Type 1 sCJD (MV1, lane 1) and type 2 sCJD (MV2, lane 8) are 
shown.  Precise PrPSc molecular subtyping for the cases as MV1 or MV2 has been previously 
reported32 and is indicated in Table 2. All samples are CC unless otherwise noted.  Case numbers 
are given above each blot and lane numbers are given below.  (B) PrPSc from 7 iCJD cases.  A 
single gel is shown with excised irrelevant lanes indicated by a thin white line.  All iCJD cases 
were type MV2 (Table 2).  The three non-CJD controls analyzed are also shown. All samples are 
CC unless otherwise noted. Case numbers or letters are given above each blot and lane numbers 
are given below. (C) The average spectral counts and standard error of the mean for PrPSc PTA-
precipitated from the 26 samples of CJD and 3 samples of non-CJD brain shown in panels A and 
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B.  Data are derived from Supplemental Table 2.  There were no significant differences in the 
average number of spectral counts between the sample groups (p=0.2, Tukey’s multiple 
comparisons test).  Black bars: sCJD MV1; gray bars: sCJD MV2; white bars: iCJD; hatched 
bars: non-CJD. 
 
Figure 3.  Differences in protein content between PTA-precipitated material from CJD and 
non-CJD brain homogenates.  (A) sCJD MV1, (B) sCJD MV2, (C) iCJD MV2, and (D) non-
CJD controls.  Creatine kinase and Dlat are present in all samples, while PrP is found at high 
abundance only in the CJD samples.  Aβ protein was found in all samples except iCJD.  For all 
panels, the data shown are derived from Table 3.  Gene and protein names are the same as in 
Table 3. 
 
Figure 4.  Regional differences in proteins co-purifying with PrPSc.  Proteins identified from 
PK-treated, PTA precipitates from the cerebellar cortex (CC) and cerebral cortex (CbC) of four 
cases of sCJD.  (A) Case 3, sCJD MV1, (B) Case 7, sCJD MV2, (C) Case 9, sCJD MV2, and (D) 
Case 14, sCJD MV2. Gene and protein names are the same as in Table 3. 
 
Figure 5.  Relative abundance of apoE and Aβ in PK-treated PTA precipitates from CJD 
brain differs by CJD type.  The average spectral counts and standard error of the mean (SpC + 
SEM) for (A) apoE and (B) Aβ . (C) The average SpC + SEM for all technical replicates for each 
CJD group (sCJD MV1 n=22, sCJD MV2 n=45, iCJD MV2 n=27, non-CJD n=9).  Using a 1-
way ANOVA multiple comparisons test with Dunnett’s post-test with non-CJD set as the control 
group, the average abundance of apoE in cases of sCJD MV1 was significantly different from 
that of the non-CJD cases (**, p < 0.01).  The relative abundance of Aβ in sCJD MV2 (***, 
p<0.001) and iCJD (****, p<0.0001) was significantly different from that of the non-CJD 
control.  For all panels, the data shown are derived from Supplemental Table 2 and represent the 
average percent abundance from 2 independent LC-MS/MS runs.  Black bars: sCJD MV1; gray 
bars: sCJD MV2; white bars: iCJD; hatched bars: non-CJD. 
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Figure 6.  Aβ1-42 peptides are present in PK-treated, PTA-precipitated sCJD and non-CJD 
brain homogenate. Representative LC-MS/MS spectra of the two unique peptides derived from 
Aβ that were found in the majority of the sCJD and non-CJD cases examined.  (A) 
LVFFAEDVGSNK represents C-terminal residues 17-28 of the Alzheimer’s disease associated 
Aβ1-42 peptide and was identified using standard trypsin search parameters. (B) 
GAIIGLMVGGVVIA represents residues 29-42 of the Aβ1-42 peptide and was found by 
removing the trypsin-specific restraints for MASCOT database searching.  Designations in blue 
denote b fragment ions and red denotes y fragment ions. 
 
Figure 7.    The Aβ1-42 peptide is present in PTA-precipitates from sCJD brain.  Samples of 
brain tissue from 3 representative cases of sCJD and all 7 samples of human-growth hormone 
associated iCJD were PTA-precipitated without PK.  Aβ1-42 and higher molecular mass Aβ 
oligomers were detected in PTA pellets from the sCJD cases while high molecular mass Aβ 
oligomers were detected in 4 of the 7 iCJD cases.  The first 2 lanes represent 5 and 10 ng 
amounts of purified Aβ1-42 peptide (arrow).  Case numbers for the sCJD and iCJD samples 
analyzed are shown above each lane.  Molecular mass markers in kilodaltons are shown on the 
left. 
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Supplemental Table 1. Proteins identified in PrPSc purified from 22L-infected and uninfected brain 
homogenate using the method of Bolton et al. 
 
 
 
 
 
 
 
aProtein identifiers are from www.uniprot.org. 
bThe total number of spectra assigned to that protein 
cthe number of unique peptides (e.g. with distinct m/z values).  
dThe sum of the highest MASCOT ion score for each unique peptide.  
IDa Centrifugation (22L-infected)  SpCb Unique peptidesc Score
d 
P04925 Major prion protein  253 10 709.7 
P09528 Ferritin heavy chain  107 10 647.2 
P29391 Ferritin light chain 1 103 12 779.1 
P49945 Ferritin light chain 2 51 6 369.5 
P08266 Apolipoprotein E  18 6 291.8 
